Suppr超能文献

替诺昔康与吡罗昔康治疗骨关节炎患者的双盲平行研究。

A double-blind parallel study of tenoxicam and piroxicam in patients with osteoarthrosis.

作者信息

Bird H A, Hill J, Dixon J S, Looi D, Wright V

出版信息

Eur J Rheumatol Inflamm. 1985;8(1):53-9.

PMID:3915888
Abstract

Tenoxicam (TILCOTIL, MOBIFLEX) 40 mg/day has been compared to piroxicam 40 mg/day in a double-blind, parallel group study of 4 weeks duration in 30 patients with osteoarthrosis. Both drugs were well tolerated, tenoxicam slightly better than piroxicam. Both drugs improved general pain, improvement being greater with tenoxicam. Little improvement of other symptoms was seen with either treatment. At the end of the study, 12 tenoxicam-treated patients and seven piroxicam-treated patients elected to remain on their respective treatment.

摘要

在一项针对30名骨关节炎患者进行的为期4周的双盲平行组研究中,对替诺昔康(痛灭定、莫比可)每日40毫克与吡罗昔康每日40毫克进行了比较。两种药物耐受性均良好,替诺昔康略优于吡罗昔康。两种药物均改善了总体疼痛,替诺昔康的改善效果更明显。两种治疗方法对其他症状的改善均不明显。研究结束时,12名接受替诺昔康治疗的患者和7名接受吡罗昔康治疗的患者选择继续接受各自的治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验